← Back to patent-cliff list
Vorasidenib
Tier C — Watch / tradeVorasidenib
Agios Pharmaceuticals Inc
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IDH1, IDH2
Brand：VORANIGO
Indications (approved)：神经胶质瘤, 少突神经胶质瘤, 星形细胞瘤, Glioma
Regional status
US
Approved
2024-08-06
EU
Approved
2025-09-17
China
Filed / under review
2026-05-08
Japan
Approved
2025-09-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vorasidenib?
Approved indications include: 神经胶质瘤, 少突神经胶质瘤, 星形细胞瘤, Glioma.
When does the Vorasidenib patent expire?
No public expiry year is available for Vorasidenib yet; this page updates once verified.
How do I get a quote for Vorasidenib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27